AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.19
-0.05 (-0.95%)
Jun 15, 2026, 1:21 PM EDT - Market open
AbCellera Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 79.21 | 75.13 | 28.83 | 38.03 | 485.42 | 375.2 | |
Revenue Growth (YoY) | 242.66% | 160.56% | -24.17% | -92.17% | 29.38% | 60.92% |
Gross Profit | 79.21 | 75.13 | 28.83 | 38.03 | 485.42 | 375.2 |
Selling, General & Admin | 59.28 | 83.23 | 85.49 | 75.18 | 66.76 | 48.76 |
Depreciation & Amortization Expenses | 23.68 | 22.17 | 90.85 | 24.4 | 27.84 | 14.45 |
Research & Development | 191 | 186.83 | 167.26 | 175.66 | 107.88 | 62.06 |
Other Operating Expenses | - | - | - | - | 66.44 | 45.52 |
Total Operating Expenses | 273.95 | 292.23 | 343.6 | 275.23 | 268.91 | 170.79 |
Operating Income | -183.38 | -217.1 | -314.77 | -237.21 | 216.51 | 204.41 |
Interest Income | 20.28 | 28.33 | 38.47 | 42.25 | 16.08 | 3.33 |
Other Non-Operating Income (Expense) | 10.25 | 11.18 | 75.9 | 20.93 | 6.51 | 11.41 |
Total Non-Operating Income (Expense) | 30.53 | 39.51 | 114.37 | 63.18 | 22.59 | 14.74 |
Pretax Income | -154.65 | -177.6 | -200.4 | -174.03 | 239.1 | 219.15 |
Provision for Income Taxes | -19.64 | -31.18 | -37.54 | -27.63 | 80.58 | 65.69 |
Net Income | -135.01 | -146.41 | -162.86 | -146.4 | 158.52 | 153.46 |
Net Income to Common | -135.01 | -146.41 | -162.86 | -146.4 | 158.52 | 153.46 |
Net Income Growth | - | - | - | - | 3.29% | 29.05% |
Shares Outstanding (Basic) | 300 | 299 | 294 | 289 | 285 | 276 |
Shares Outstanding (Diluted) | 300 | 299 | 294 | 289 | 315 | 318 |
Shares Change (YoY) | 1.52% | 1.49% | 1.79% | -8.15% | -1.09% | 20.96% |
EPS (Basic) | -0.48 | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 |
EPS (Diluted) | -0.48 | -0.49 | -0.55 | -0.51 | 0.50 | 0.48 |
EPS Growth | - | - | - | - | 4.17% | 6.67% |
Free Cash Flow | -189.23 | -174.07 | -186.95 | -120.82 | 206.7 | 186.13 |
Free Cash Flow Growth | - | - | - | - | 11.05% | 1329.91% |
Free Cash Flow Per Share | -0.63 | -0.58 | -0.64 | -0.42 | 0.66 | 0.58 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -231.52% | -288.98% | -1091.69% | -623.82% | 44.60% | 54.48% |
Profit Margin | -170.45% | -194.88% | -564.83% | -385.00% | 32.66% | 40.90% |
FCF Margin | -238.91% | -231.69% | -648.40% | -317.75% | 42.58% | 49.61% |
EBITDA | -152.51 | -188.28 | -217.77 | -206.31 | 249.61 | 221.66 |
EBITDA Margin | -192.55% | -250.61% | -755.27% | -542.57% | 51.42% | 59.08% |
EBIT | -183.38 | -217.1 | -314.77 | -237.21 | 216.51 | 204.41 |
EBIT Margin | -231.52% | -288.98% | -1091.69% | -623.82% | 44.60% | 54.48% |
Effective Tax Rate | 12.70% | 17.56% | 18.73% | 15.88% | 33.70% | 29.97% |